Anticoagulation in Liver Fibrosis
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to respond to anti-viral treatment are often concerned about their ongoing liver disease and are therefore looking for alternative treatments which might prevent fibrosis progression. This view is endorsed by patient representative groups (including Charles Gore at the HepC Trust) who have welcomed this trial protocol.
The trial will be a randomised cross over study with 15 patients in each group. Each patient will receive eight weeks of anticoagulation and eight weeks of observation.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Anticoagulation for Liver Fibrosis in Patients With Hepatitis C Virus Infection: Pilot Study|
- Reduction in fibrosis biomarkers
|Study Start Date:||August 2005|
|Study Completion Date:||October 2006|
|Primary Completion Date:||September 2006 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180674
|St Mary's Hospital NHS Trust|
|London, United Kingdom, W2 1NY|
|Principal Investigator:||Mark R Thursz, MBBS, FRCP||St Mary's Hospital & Imperial College London|